<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03172936</url>
  </required_header>
  <id_info>
    <org_study_id>CMIW815X2102J</org_study_id>
    <secondary_id>2017-000707-25</secondary_id>
    <nct_id>NCT03172936</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas</brief_title>
  <official_title>A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors or Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety, tolerability, pharmacokinetics,
      pharmacodynamics and antitumor activity of MIW815 (ADU-S100) in combination with PDR001.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase Ib, multi-center, open-label study to characterize the safety, tolerability,
      pharmacokinetics, pharmacodynamics and preliminary antitumor activity of MIW815(ADU-S100) in
      combination with the PD-1 checkpoint inhibitor PDR001. Two different schedules will be
      explored in two dose escalation groups in accessible cutaneous or subcutaneous lesions, as
      well as an optional dose confirmation group exploring intratumoral injection of viscerally
      located lesions.

      Group A will include patients with accessible solid tumors and lymphomas. This group will
      receive a fixed dose of PDR001 i.v. on day 1 of every 28 day cycle and intratumoral
      injections of MIW815 (ADU-S100) on days 1, 8 and 15 of every 28 day cycle. Group B will
      include patients with accessible solid tumors and lymphomas. This group will receive a fixed
      dose of PDR001 i.v. on day 1 of every cycle and an intratumoral injection of MIW815
      (ADU-S100) on day 1 of every cycle.

      Once the dose and dose schedule has been confirmed, the dose expansion part of the study will
      open. The main purpose of the expansion part is to further assess the safety and
      tolerability, as well as preliminary anti-tumor activity, of the study treatment at the
      maximum tolerated dose and/or recommended dose for expansion. .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2017</start_date>
  <completion_date type="Anticipated">February 16, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 9, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study is comprised of two treatment arms.
Group A will include patients with accessible solid tumors and lymphomas. This group will receive a fixed dose of PDR001 intravenous on day 1 of every 28 day cycle and intratumoral injections of MIW815 (ADU-S100) on days 1, 8 and 15 of every 28 day cycle.
Group B will include patients with accessible solid tumors and lymphomas. This group will receive a fixed dose of PDR001 intravenous on day 1 of every cycle and an intratumoral injection of MIW815 (ADU-S100) on day 1 of every cycle.
Once the maximum tolerated dose and/or recommended dose for expansion is determined, the expansion part of the study will open.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLTs)</measure>
    <time_frame>24 months</time_frame>
    <description>A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first cycle of treatment with the combination of MIW815 (ADU-S100) and PDR001</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC last</measure>
    <time_frame>36 months</time_frame>
    <description>The area under the concentration (AUC) -time curve calculated to the last quantifiable concentration point (mass* time/volume)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC tau</measure>
    <time_frame>36 months</time_frame>
    <description>Area under the concentration-time curve calculated to the end of the dosing interval (tau) (mass* time/volume)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC inf</measure>
    <time_frame>36 months</time_frame>
    <description>The area under the concentration-time curve extrapolated to infinity (mass*time/volume)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>36 months</time_frame>
    <description>The maximum observed concentration (Cmax) following dose administration (mass/volume)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>36 months</time_frame>
    <description>The time to reach the maximum observed concentration (time)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin</measure>
    <time_frame>36 months</time_frame>
    <description>Minimum observed plasma concentration (mass/volume)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lambda_z</measure>
    <time_frame>36 months</time_frame>
    <description>Terminal elimination rate constant (1/time)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>36 months</time_frame>
    <description>Elimination half-life, determined as 0.693/Lambda_z (time)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>36 months</time_frame>
    <description>Apparent systemic clearance of drug from the plasma (volume x time -1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F</measure>
    <time_frame>36 months</time_frame>
    <description>Apparent volume of distribution during the terminal elimination phase (volume)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR)</measure>
    <time_frame>36 months</time_frame>
    <description>Best overall response will be summarized with accompanying 90% exact binomial confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>36 months</time_frame>
    <description>Overall response rate will be summarized with accompanying 90% exact binomial confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>36 months</time_frame>
    <description>The survival function will be estimated using the Kaplan-Meier product limit method. Median duration, with a two-sided Brookmeyer-Crowley 90% confidence interval and Kaplan-Meier estimates of survival proportions will be provided at specified time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>36 months</time_frame>
    <description>The disease control rate is calculated as the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>36 months</time_frame>
    <description>Kaplan-Meier estimates may be provided if sufficient numbers of patients respond.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor infiltrating lymphocytes (TIL)</measure>
    <time_frame>36 months</time_frame>
    <description>Induction of TILs in the injected lesion (local PD effect) and in a non-injected lesion (distal PD effect) will be assessed using paired tumor samples at screening and on-treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines</measure>
    <time_frame>36 months</time_frame>
    <description>Induction of cytokines in the injected lesion (local PD effect) and in a non-injected lesion (distal PD effect) will be assessed using paired tumor samples at screening and on-treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in mutation burden in tumor and in circulation</measure>
    <time_frame>36 months</time_frame>
    <description>Changes from baseline in DNA tumor sample in injected and distal lesions and in cell free (cf) DNA at end of study treatment.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Solid Tumors and Lymphomas</condition>
  <arm_group>
    <arm_group_label>Dosing Schedule A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with MIW815 (ADU-S100) via intratumoral injection for 3 weeks on followed by one week off in combination with a fixed intravenous dose of PDR001 given once per month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing Schedule B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with MIW815 (ADU-S100) via intratumoral injection given once a month in combination with a fixed intravenous dose of PDR001 given once per month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MIW815</intervention_name>
    <description>MIW 815 (ADU-S100) is a STING agonist</description>
    <arm_group_label>Dosing Schedule A</arm_group_label>
    <arm_group_label>Dosing Schedule B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <description>PDR001 is an anti-PD-1 antibody</description>
    <arm_group_label>Dosing Schedule A</arm_group_label>
    <arm_group_label>Dosing Schedule B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        ECOG â‰¤ 1 Willing to undergo tumor biopsies from injected and distal lesions

        Must have two biopsy accessible lesions:

        Exclusion Criteria:

        Symptomatic or untreated leptomeningeal disease. Presence of symptomatic central nervous
        system metastases Impaired cardiac function or clinically significant cardiac disease
        Active autoimmune disease or a documented history of autoimmune disease, except vitiligo or
        resolved childhood asthma/atopy.

        Active infection requiring systemic antibiotic therapy. Known history of human
        immunodeficiency virus infection. Active Epstein-Barr virus, hepatitis B virus or hepatitis
        C virus Malignant disease, other than that being treated in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy Lewis, MD</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>Novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Chicago Medical Center SC</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Rainer</last_name>
      <phone>773-702-2085</phone>
      <email>mrainer@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Luke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nilza Biaggi Labiosa</last_name>
      <phone>+1 713 745 4453</phone>
      <email>NMBiaggi@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Funda Meric-Bernstam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2017</study_first_submitted>
  <study_first_submitted_qc>May 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>injected lesion</keyword>
  <keyword>distal lesion</keyword>
  <keyword>abscopal activity</keyword>
  <keyword>intratumoral</keyword>
  <keyword>checkpoint inhibitor</keyword>
  <keyword>cyclic dinucleotide</keyword>
  <keyword>programmed cell death</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

